Oncologists monitor treatment progress through a combination of medical imaging, laboratory tests, physical examinations, and standardized response criteria. These tools allow clinical researchers and oncology teams to objectively assess how a tumor is responding over time. The sections below unpack each major method, from imaging protocols to biomarker analysis and decision-making frameworks.
What tools do oncologists use to assess treatment response?
Oncologists use a structured set of diagnostic tools to track how cancer responds to treatment. The core methods are medical imaging, blood-based laboratory tests, tissue biopsies, and clinical examinations. No single tool provides a complete picture, so oncologists typically combine several approaches to build an accurate assessment of treatment response.
Imaging in oncology is central to tumor response assessment. Computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound each offer different types of information. CT and MRI measure changes in tumor size and structure. PET imaging detects metabolic activity, which can reveal whether cancer cells remain active even when a tumor appears structurally unchanged.
Alongside imaging, laboratory tests play an essential role. Blood tests can reveal changes in circulating tumor markers, cell counts, and organ function. In research settings, liquid biopsies that analyze cell-free DNA or circulating tumor cells are increasingly used to track molecular changes in real time.
Physical examination and patient-reported outcomes round out the clinical picture, particularly for surface-level tumors or symptoms that imaging cannot fully capture.
What are the standard criteria for measuring tumor response?
The most widely used standard for measuring tumor response in oncology research is the RECIST framework, which stands for Response Evaluation Criteria in Solid Tumors. RECIST provides a structured, reproducible method for categorizing how a tumor changes in size during or after treatment, based on measurements taken from imaging studies.
Under RECIST guidelines, tumor response falls into four categories:
- Complete response (CR): All target lesions have disappeared
- Partial response (PR): A meaningful reduction in the sum of target lesion diameters
- Stable disease (SD): Neither sufficient shrinkage nor sufficient growth to qualify as a response or progression
- Progressive disease (PD): Growth in target lesions or the appearance of new lesions
For blood cancers and other non-solid tumors, different criteria apply. Lymphoma research uses the Lugano classification, while hematological malignancies often rely on bone marrow assessments and blood cell counts rather than lesion measurements.
These standardized frameworks are essential in clinical research because they allow results to be compared across studies and institutions, providing a consistent language for evaluating cancer treatment monitoring data.
How do blood-based biomarkers help track cancer treatment?
Blood-based biomarkers help oncologists track cancer treatment by providing measurable indicators of tumor activity, treatment response, and disease recurrence without requiring invasive tissue sampling. Common biomarkers include proteins secreted by tumors, genetic material shed into the bloodstream, and immune cell populations that shift in response to treatment.
Tumor markers such as prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and CA-125 have been used for decades to track certain cancer types. Rising or falling levels over time can signal whether a treatment is having the intended effect, though these markers are interpreted alongside imaging and clinical findings rather than in isolation.
Liquid biopsy technology represents a more recent development in cancer biomarker research. By analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in a blood sample, researchers can detect molecular changes that may precede visible tumor growth or shrinkage. This approach is being investigated as a way to identify early resistance to treatment and to monitor minimal residual disease after therapy.
In research environments across the Benelux region, laboratory instruments used for biomarker analysis include multimode readers, liquid handling systems, and microplate-based assay platforms, all of which support the high-throughput and reproducible workflows that biomarker research demands.
How often do oncologists schedule monitoring assessments?
The frequency of monitoring assessments in oncology depends on the cancer type, treatment phase, and the specific protocol being followed. In active treatment phases, imaging assessments are typically scheduled every two to three treatment cycles, which often translates to every six to twelve weeks. Blood tests and clinical evaluations may occur more frequently, sometimes at every treatment visit.
During follow-up after treatment completion, monitoring intervals are generally extended. Early follow-up may involve assessments every three to six months, with intervals lengthening to annually as time passes without recurrence. The rationale is that the risk of recurrence is highest in the period immediately following treatment.
In research settings, monitoring schedules are defined by the study protocol and must be followed consistently to generate reliable data. Deviations from the scheduled timeline can affect the validity of response assessments and the comparability of results across study participants.
What’s the difference between response, remission, and cure in oncology?
In oncology, response, remission, and cure describe different stages and degrees of treatment outcome, and the terms are not interchangeable. Understanding the distinction is important for interpreting research findings and communicating accurately about treatment progress.
Response refers to a measurable change in tumor size or activity following treatment. A complete response means no detectable disease remains on imaging or in laboratory tests. A partial response means the tumor has shrunk but is still detectable. Response is a short-term measurement tied to a specific assessment point.
Remission describes a sustained period in which signs and symptoms of cancer are reduced or absent. Complete remission means no evidence of disease is detectable over a defined period. Remission does not mean the cancer is gone permanently; it means it is not currently measurable. The duration of remission is often used as a research endpoint.
Cure is a term used cautiously in oncology research. It implies that the cancer will not return, which is difficult to confirm given that some cancers can recur years or decades after treatment. In research contexts, long-term disease-free survival is often used as a more precise and verifiable endpoint than “cure.”
How do oncologists adjust treatment based on monitoring results?
Oncologists adjust treatment based on monitoring results by evaluating whether the current approach is achieving the desired response, causing unacceptable side effects, or showing signs of resistance. Monitoring data directly informs decisions to continue, modify, pause, or change a treatment regimen.
The decision-making process typically follows a structured sequence:
- Assess response category: Imaging and biomarker data are reviewed against standard criteria such as RECIST to classify the current response
- Evaluate tolerability: Laboratory results and clinical findings are used to assess organ function and treatment-related toxicity
- Identify resistance signals: Molecular testing or liquid biopsy may reveal emerging resistance mutations that predict treatment failure
- Review the overall trajectory: A single assessment point is interpreted in the context of all prior results to identify trends
- Make a protocol-based decision: In clinical research, adjustments follow predefined criteria in the study protocol to ensure consistency and scientific integrity
In research settings, these decisions are governed by the study protocol and reviewed by multidisciplinary teams. The goal is not only to optimize outcomes for individual participants but also to generate reliable, reproducible data that advances the understanding of how oncologists track treatment response across populations.
How BioSPX supports oncology research in the Benelux
Supporting the laboratory workflows that underpin cancer treatment monitoring requires reliable, high-performance instrumentation. Research teams in Belgium, the Netherlands, and Luxembourg working on tumor response assessment, biomarker analysis, and cell-based assays depend on instruments that deliver reproducible results at scale.
BioSPX provides life science laboratories in the Benelux region with a broad portfolio of instruments suited to oncology research workflows, including:
- Multimode readers for absorbance, fluorescence, and luminescence-based biomarker assays
- Microplate washers and dispensers for high-throughput sample processing
- Imaging and microscopy systems for cellular and molecular analysis
- Liquid handling solutions that support consistent, automated sample preparation
- Cell culture automation tools such as the Discover Nestor system, which automates routine tasks across multiple flasks and multiwell plates
BioSPX’s product specialists advise on instrument selection, experimental setup, and system configuration, while the service department ensures correct installation and rapid maintenance response. If you are equipping or upgrading a laboratory involved in oncology research, contact BioSPX to discuss the right solution for your workflow.
Frequently Asked Questions
What is the difference between measurable and non-measurable lesions in RECIST?
Under RECIST guidelines, measurable lesions are those that can be accurately measured in at least one dimension, typically requiring a minimum size threshold (e.g., ≥10 mm on CT). Non-measurable lesions include small lesions below that threshold, bone lesions, pleural effusions, and other findings that cannot be reliably quantified. In a RECIST assessment, only measurable target lesions are used to calculate the sum of diameters and classify response, while non-target lesions are still tracked qualitatively to detect progression.
How reliable are tumor markers like PSA or CA-125 on their own for monitoring treatment response?
Tumor markers alone are generally not sufficient to determine treatment response and should always be interpreted alongside imaging and clinical findings. Marker levels can fluctuate due to factors unrelated to tumor activity, such as inflammation, organ dysfunction, or assay variability, leading to potential false positives or negatives. For example, a transient PSA rise shortly after starting certain therapies — known as a PSA flare — can be misinterpreted as progression if not contextualized within the broader clinical picture. Most oncology guidelines explicitly caution against making treatment decisions based on biomarker data in isolation.
What are the main challenges of using liquid biopsy in routine oncology research workflows?
Liquid biopsy is a promising technology, but several practical challenges remain in translating it into routine research workflows. Circulating tumor DNA concentrations in blood can be extremely low, particularly in early-stage disease or after successful treatment, requiring highly sensitive detection platforms and rigorous sample handling protocols to avoid degradation or contamination. Standardization is also an ongoing challenge — differences in pre-analytical variables such as blood collection tubes, centrifugation protocols, and storage conditions can significantly affect results, making cross-study comparisons difficult. Research teams adopting liquid biopsy workflows typically invest in validated liquid handling systems and assay platforms to maintain reproducibility.
How do clinical research teams handle discordant results — for example, when imaging shows stable disease but a biomarker is rising?
Discordant results — where imaging and biomarker data point in different directions — are a recognized challenge in oncology monitoring and require careful clinical interpretation. In research settings, the study protocol typically defines how conflicting data should be handled, often requiring additional confirmatory assessments before a response category is changed. A rising biomarker in the context of stable imaging may prompt earlier re-imaging, molecular testing for resistance mutations, or a multidisciplinary team review. The key principle is that no single data point drives a decision; the full trajectory of all available monitoring data is considered together.
What is pseudoprogression, and why does it matter for treatment monitoring?
Pseudoprogression is a phenomenon in which a tumor appears to grow or new lesions appear on imaging shortly after starting treatment, even though the therapy is actually working. It is most commonly observed with immunotherapy, where an initial inflammatory response can cause temporary tumor swelling before the immune-mediated tumor kill becomes apparent. Misidentifying pseudoprogression as true disease progression can lead to the premature discontinuation of an effective treatment. Oncology research teams monitoring immunotherapy trials must account for this possibility, often by continuing treatment and scheduling a confirmatory scan before classifying a result as progressive disease.
How should a research laboratory get started with setting up an oncology biomarker monitoring workflow?
Setting up a robust oncology biomarker monitoring workflow starts with clearly defining the assay types and throughput requirements your research demands — for example, whether you need ELISA-based protein quantification, ctDNA detection, or cell-based functional assays. From there, instrument selection should prioritize reproducibility, sensitivity, and compatibility with validated assay kits relevant to your target biomarkers. It is also worth investing early in standardized sample collection and processing protocols, as pre-analytical variability is one of the most common sources of unreliable data in biomarker research. Consulting with an instrument specialist familiar with oncology workflows — such as the team at BioSPX for laboratories in the Benelux region — can help align equipment choices with your specific experimental and throughput needs.
What is minimal residual disease (MRD) and how is it measured?
Minimal residual disease (MRD) refers to the small number of cancer cells that may remain in the body after treatment when the patient appears to be in complete remission by standard clinical assessments. Detecting MRD is important because its presence is associated with a higher risk of relapse, even when no disease is visible on imaging or in routine blood tests. MRD is most commonly measured using highly sensitive molecular techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), or flow cytometry, depending on the cancer type. In hematological malignancies in particular, MRD status has become an important research endpoint and is increasingly used to guide decisions about treatment duration and post-remission therapy.
Related Articles
- How does FLIM-FRET preserve spatial information that bulk assays lose?
- How does angiogenesis support tumor growth at the cellular level?
- How can researchers measure real-time changes in cancer cell morphology?
- What can continuous cell monitoring reveal that endpoint assays cannot?
- What is the difference between primary and secondary cancer?
This content was generated with the help of AI and it may contain mistakes